DGIdb - LENALIDOMIDE Drug Record

LENALIDOMIDE chembl:CHEMBL848 ApprovedAntineoplasticImmunotherapy

Alternate Names:

LENALIDOMIDE
SYP-1512
CC-5013
REVLIMID
CDC-501
1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOISOINDOLINE
CDC 501
IMID3
REVLIMID®
3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
IMID-1
rxcui:342369
pubchem.compound:216326
chembl:CHEMBL848
chemidplus:191732-72-6
drugbank:00480

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(4 More Sources)

Publications:

Bertino et al., 2016, A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer., Mol. Cancer Ther.
Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res
Melchert et al., 2007, The thalidomide saga., Int. J. Biochem. Cell Biol.
Akobeng et al., 2009, Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease., Cochrane Database Syst Rev
Zhu et al., 2013, Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma., Leuk. Lymphoma
Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.
Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
Krönke et al., 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells., Science
Jakobsen Falk I et al., 2018, Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial., Cancer Chemother Pharmacol

LENALIDOMIDE CRBN

Interaction Score: 3.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
22966948 23480694

Sources:
ChemblInteractions CIViC
LENALIDOMIDE TNFSF11

Interaction Score: 3.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Revlimid

PMIDs:
17369076 19370685

Sources:
TdgClinicalTrial
LENALIDOMIDE DDB1

Interaction Score: 1.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LENALIDOMIDE IKZF1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type multiple myeloma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24292625

Sources:
JAX-CKB
LENALIDOMIDE CUL4A

Interaction Score: 1.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
LENALIDOMIDE VEGFB

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
LENALIDOMIDE RBX1

Interaction Score: 0.74

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LENALIDOMIDE VEGFC

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
LENALIDOMIDE CTNNB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB
LENALIDOMIDE FGF2

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28373444

Sources:
PharmGKB
LENALIDOMIDE TNF

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TTD
LENALIDOMIDE VEGFA

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
LENALIDOMIDE KRAS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + lenalidomide

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

PMIDs:
27458141

Sources:
JAX-CKB
LENALIDOMIDE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177954

Sources:
PharmGKB

TdgClinicalTrial: LENALIDOMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: lenalidomide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Jakobsen Falk I et al., 2018, Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial., Cancer Chemother Pharmacol

Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res

Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

JAX-CKB: lenalidomide

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Krönke et al., 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells., Science

Bertino et al., 2016, A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer., Mol. Cancer Ther.

CIViC: LENALIDOMIDE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.

TTD: Lenalidomide
- Version: 2020.06.01
Alternate Names:

D0Q5NX TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL848
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: LENALIDOMIDE
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL848
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	CRL4(CRBN) E3 ubiquitin ligase inhibitor
Direct Interaction	yes

Indication/Tumor Type	multiple myeloma
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Cetuximab + lenalidomide
Indication/Tumor Type	colorectal cancer
Response Type	predicted – sensitive

Novel drug target	Established target
Trial Name	Revlimid

LENALIDOMIDE Drug Record

LENALIDOMIDE chembl:CHEMBL848 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor Direct Interaction yes

PMIDs: 22966948 23480694

Sources: ChemblInteractions CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Revlimid

PMIDs: 17369076 19370685

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type multiple myeloma Response Type sensitive Approval Status Preclinical

PMIDs: 24292625

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26521987

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28373444

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cetuximab + lenalidomide Indication/Tumor Type colorectal cancer Response Type predicted – sensitive

PMIDs: 27458141

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29177954

Sources: PharmGKB

TdgClinicalTrial: LENALIDOMIDE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

PharmGKB: lenalidomide

Alternate Names:

Drug Info:

JAX-CKB: lenalidomide

Alternate Names:

Drug Info:

CIViC: LENALIDOMIDE

Alternate Names:

Drug Info:

Publications: Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.

TTD: Lenalidomide

Alternate Names: D0Q5NX TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL848

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
22966948 23480694

Sources:
ChemblInteractions CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Revlimid

PMIDs:
17369076 19370685

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type multiple myeloma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24292625

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
26521987

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28373444

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + lenalidomide

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

PMIDs:
27458141

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
29177954

Sources:
PharmGKB

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.

Alternate Names:

D0Q5NX TTD Drug ID